<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36754974</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Potential antiviral effects of pantethine against SARS-CoV-2.</ArticleTitle><Pagination><StartPage>2237</StartPage><MedlinePgn>2237</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2237</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-29245-0</ELocationID><Abstract><AbstractText>SARS-CoV-2 interacts with cellular cholesterol during many stages of its replication cycle. Pantethine was reported to reduce total cholesterol levels and fatty acid synthesis and potentially alter different processes that might be involved in the SARS-CoV-2 replication cycle. Here, we explored the potential antiviral effects of pantethine in two in vitro experimental models of SARS-CoV-2 infection, in Vero E6 cells and in Calu-3a cells. Pantethine reduced the infection of cells by SARS-CoV-2 in both preinfection and postinfection treatment regimens. Accordingly, cellular expression of the viral spike and nucleocapsid proteins was substantially reduced, and we observed a significant reduction in viral copy numbers in the supernatant of cells treated with pantethine. In addition, pantethine inhibited the infection-induced increase in TMPRSS2 and HECT E3 ligase expression in infected cells as well as the increase in antiviral interferon-beta response and inflammatory gene expression in Calu-3a cells. Our results demonstrate that pantethine, which is well tolerated in humans, was very effective in controlling SARS-CoV-2 infection and might represent a new therapeutic drug that can be repurposed for the prevention or treatment of COVID-19 and long COVID syndrome.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Abou-Hamdan</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biology Department, Faculty of Sciences (I), Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Saleh</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mani</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dournaud</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metifiot</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Bordeaux, CNRS, UMR 5234, Microbiologie Fondamentale et Pathog&#xe9;nicit&#xe9;, 33076, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blondot</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Bordeaux, CNRS, UMR 5234, Microbiologie Fondamentale et Pathog&#xe9;nicit&#xe9;, 33076, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreola</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Bordeaux, CNRS, UMR 5234, Microbiologie Fondamentale et Pathog&#xe9;nicit&#xe9;, 33076, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Sater</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biochemistry Department, Faculty of Sciences (I), Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Reggi</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gressens</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laforge</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NeuroDiderot, Inserm, Universit&#xe9; Paris Cit&#xe9;, 48 Boulevard S&#xe9;rurier, 75019, Paris, France. mireille.laforge@inserm.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7K81IL792L</RegistryNumber><NameOfSubstance UI="C005425">pantethine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>S.M., P.D., M.M., ML.A., F.AS., and P.G. declare no conflicts of interest. M.AH., R.S., M.dR. and M.L. have a patent pending for pantethine use as a treatment for COVID-19.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36754974</ArticleId><ArticleId IdType="pmc">PMC9906591</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-29245-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-29245-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreano E, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020 doi: 10.1101/2020.12.28.424451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.28.424451</ArticleId><ArticleId IdType="pmc">PMC8433494</ArticleId><ArticleId IdType="pubmed">34417349</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisblum Y, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020 doi: 10.7554/eLife.61312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61312</ArticleId><ArticleId IdType="pmc">PMC7723407</ArticleId><ArticleId IdType="pubmed">33112236</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671&#x2013;675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M, et al. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: A triple-blinded placebo and diet-controlled investigation. Vasc. Health Risk Manag. 2014;10:89&#x2013;100. doi: 10.2147/VHRM.S57116.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S57116</ArticleId><ArticleId IdType="pmc">PMC3942300</ArticleId><ArticleId IdType="pubmed">24600231</ArticleId></ArticleIdList></Reference><Reference><Citation>McRae MP. Treatment of hyperlipoproteinemia with pantethine: A review and analysis of efficacy and tolerability. Nutr. Res. 2005;25:319&#x2013;333. doi: 10.1016/j.nutres.2004.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nutres.2004.12.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gijsel-Bonnello M, et al. Pantethine alters lipid composition and cholesterol content of membrane rafts, with down-regulation of CXCL12-induced T cell migration. J. Cell. Physiol. 2015;230:2415&#x2013;2425. doi: 10.1002/jcp.24971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.24971</ArticleId><ArticleId IdType="pubmed">25728249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Commun. 2008;369:344&#x2013;349. doi: 10.1016/j.bbrc.2008.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.02.023</ArticleId><ArticleId IdType="pmc">PMC7092920</ArticleId><ArticleId IdType="pubmed">18279660</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios-R&#xe1;palo SN, et al. Cholesterol-rich lipid rafts as platforms for SARS-CoV-2 entry. Front. Immunol. 2021;12:796855. doi: 10.3389/fimmu.2021.796855.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.796855</ArticleId><ArticleId IdType="pmc">PMC8719300</ArticleId><ArticleId IdType="pubmed">34975904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. Elife. 2021 doi: 10.7554/eLife.65962.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.65962</ArticleId><ArticleId IdType="pmc">PMC8104966</ArticleId><ArticleId IdType="pubmed">33890572</ArticleId></ArticleIdList></Reference><Reference><Citation>Glende J, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology. 2008;381:215&#x2013;221. doi: 10.1016/j.virol.2008.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.08.026</ArticleId><ArticleId IdType="pmc">PMC7103374</ArticleId><ArticleId IdType="pubmed">18814896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Musarrat F, et al. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J. Med. Virol. 2020;92:2087&#x2013;2095. doi: 10.1002/jmv.25985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25985</ArticleId><ArticleId IdType="pmc">PMC7267418</ArticleId><ArticleId IdType="pubmed">32374457</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18:290&#x2013;301. doi: 10.1038/cr.2008.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2008.15</ArticleId><ArticleId IdType="pmc">PMC7091891</ArticleId><ArticleId IdType="pubmed">18227861</ArticleId></ArticleIdList></Reference><Reference><Citation>Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9:96&#x2013;102. doi: 10.1016/j.micinf.2006.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.10.015</ArticleId><ArticleId IdType="pmc">PMC7110773</ArticleId><ArticleId IdType="pubmed">17194611</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann&#x2013;Pick disease type C, with therapeutic implications. FASEB J. 2020;34:7253&#x2013;7264. doi: 10.1096/fj.202000654R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202000654R</ArticleId><ArticleId IdType="pmc">PMC7383733</ArticleId><ArticleId IdType="pubmed">32367579</ArticleId></ArticleIdList></Reference><Reference><Citation>A Detailed Study of Patients with Long-Haul COVID. An Analysis of Private Healthcare Claims (2021).</Citation></Reference><Reference><Citation>Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: A systematic review and meta-analysis. Heart. 2021;107:373&#x2013;380. doi: 10.1136/heartjnl-2020-317901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2020-317901</ArticleId><ArticleId IdType="pubmed">33334865</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pan Y, Yin Y, Chen W, Li X. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): A meta-analysis. Virol. J. 2021;18:157. doi: 10.1186/s12985-021-01604-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01604-1</ArticleId><ArticleId IdType="pmc">PMC8314261</ArticleId><ArticleId IdType="pubmed">34315474</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue J, et al. Dyslipidemia is related to mortality in critical patients with coronavirus disease 2019: A retrospective study. Front. Endocrinol. (Lausanne) 2021;12:611526. doi: 10.3389/fendo.2021.611526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.611526</ArticleId><ArticleId IdType="pmc">PMC8261125</ArticleId><ArticleId IdType="pubmed">34248834</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, et al. Risk factors associated with long COVID syndrome: A retrospective study. Iran. J. Med. Sci. 2021;46:428&#x2013;436. doi: 10.30476/ijms.2021.92080.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.30476/ijms.2021.92080.2326</ArticleId><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustarini D, Santucci A, Bartolini D, Galli F, Rossi R. The age-dependent decline of the extracellular thiol-disulfide balance and its role in SARS-CoV-2 infection. Redox Biol. 2021;41:101902. doi: 10.1016/j.redox.2021.101902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2021.101902</ArticleId><ArticleId IdType="pmc">PMC7889000</ArticleId><ArticleId IdType="pubmed">33662873</ArticleId></ArticleIdList></Reference><Reference><Citation>Debnath, U., Mitra, A., Dewaker, V., Prabhakar, Y. S., Tadala, R., Krishnan, K. et al. N-acetyl cysteine: A tool to perturb SARS-CoV-2 spike protein conformation. ChemRxiv (Cambridge Open Engage, 2021).</Citation></Reference><Reference><Citation>De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020;34:13185&#x2013;13193. doi: 10.1096/fj.202001807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202001807</ArticleId><ArticleId IdType="pmc">PMC7436914</ArticleId><ArticleId IdType="pubmed">32780893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hati S, Bhattacharyya S. Impact of thiol-disulfide balance on the binding of Covid-19 spike protein with angiotensin-converting enzyme 2 receptor. ACS Omega. 2020;5:16292&#x2013;16298. doi: 10.1021/acsomega.0c02125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.0c02125</ArticleId><ArticleId IdType="pmc">PMC7346263</ArticleId><ArticleId IdType="pubmed">32656452</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge-Aar&#xf3;n RM, Rosa-Ester MP. N-acetylcysteine as a potential treatment for COVID-19. Future Microbiol. 2020;15:959&#x2013;962. doi: 10.2217/fmb-2020-0074.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2020-0074</ArticleId><ArticleId IdType="pmc">PMC7359418</ArticleId><ArticleId IdType="pubmed">32662664</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virol. J. 2019;16:69. doi: 10.1186/s12985-019-1182-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1182-0</ArticleId><ArticleId IdType="pmc">PMC6537279</ArticleId><ArticleId IdType="pubmed">31133031</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma D, Kapoor S, Das S, Thakur K. Main protease (Mpro) identified from the library of FDA approved drugs using molecular docking studies. Biomedicines. 2020 doi: 10.20944/preprints202004.0149.v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.20944/preprints202004.0149.v1</ArticleId><ArticleId IdType="pmc">PMC9856154</ArticleId><ArticleId IdType="pubmed">36672593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco MD, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci. Adv. 2020 doi: 10.1126/sciadv.abe0751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe0751</ArticleId><ArticleId IdType="pmc">PMC7725459</ArticleId><ArticleId IdType="pubmed">33158912</ArticleId></ArticleIdList></Reference><Reference><Citation>Penet MF, et al. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc. Natl. Acad. Sci. U.S.A. 2008;105:1321&#x2013;1326. doi: 10.1073/pnas.0706867105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0706867105</ArticleId><ArticleId IdType="pmc">PMC2234136</ArticleId><ArticleId IdType="pubmed">18195363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornille E, et al. Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury. BMC Neurosci. 2010;11:51. doi: 10.1186/1471-2202-11-51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-11-51</ArticleId><ArticleId IdType="pmc">PMC2880308</ArticleId><ArticleId IdType="pubmed">20416081</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10:7448&#x2013;7464. doi: 10.7150/thno.48076.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.48076</ArticleId><ArticleId IdType="pmc">PMC7330865</ArticleId><ArticleId IdType="pubmed">32642005</ArticleId></ArticleIdList></Reference><Reference><Citation>Dittmar M, et al. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep. 2021;35:108959. doi: 10.1016/j.celrep.2021.108959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108959</ArticleId><ArticleId IdType="pmc">PMC7985926</ArticleId><ArticleId IdType="pubmed">33811811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020;585:588&#x2013;590. doi: 10.1038/s41586-020-2575-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2575-3</ArticleId><ArticleId IdType="pubmed">32698190</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U.S.A. 2020;117:7001&#x2013;7003. doi: 10.1073/pnas.2002589117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BK, et al. Differential signaling and virus production in Calu-3 cells and Vero cells upon SARS-CoV-2 infection. Biomol. Ther. (Seoul) 2021;29:273&#x2013;281. doi: 10.4062/biomolther.2020.226.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2020.226</ArticleId><ArticleId IdType="pmc">PMC8094074</ArticleId><ArticleId IdType="pubmed">33504682</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli G, et al. Inhibition of HECT E3 ligases as potential therapy for COVID-19. Cell Death Dis. 2021;12:310. doi: 10.1038/s41419-021-03513-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03513-1</ArticleId><ArticleId IdType="pmc">PMC7987752</ArticleId><ArticleId IdType="pubmed">33762578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui Y, Li J, Venzon DJ, Berzofsky JA. SARS-CoV-2 spike protein suppresses ACE2 and type I interferon expression in primary cells from macaque lung bronchoalveolar lavage. Front. Immunol. 2021;12:658428. doi: 10.3389/fimmu.2021.658428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658428</ArticleId><ArticleId IdType="pmc">PMC8213020</ArticleId><ArticleId IdType="pubmed">34149696</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry. Nat. Commun. 2021;12:3907. doi: 10.1038/s41467-021-24156-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24156-y</ArticleId><ArticleId IdType="pmc">PMC8222394</ArticleId><ArticleId IdType="pubmed">34162861</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizio JD, et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature. 2022;603:145&#x2013;151. doi: 10.1038/s41586-022-04421-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04421-w</ArticleId><ArticleId IdType="pmc">PMC8891013</ArticleId><ArticleId IdType="pubmed">35045565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebendenne A, et al. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J. Virol. 2021 doi: 10.1128/JVI.02415-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02415-20</ArticleId><ArticleId IdType="pmc">PMC8103705</ArticleId><ArticleId IdType="pubmed">33514628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 2021;34:108628. doi: 10.1016/j.celrep.2020.108628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108628</ArticleId><ArticleId IdType="pmc">PMC7832566</ArticleId><ArticleId IdType="pubmed">33440148</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeldt CJ, et al. SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-kappaB. Commun. Biol. 2022;5:45. doi: 10.1038/s42003-021-02983-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02983-5</ArticleId><ArticleId IdType="pmc">PMC8755718</ArticleId><ArticleId IdType="pubmed">35022513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajimaya S, Frankl T, Hayashi T, Takimoto T. Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses. Virology. 2017;510:234&#x2013;241. doi: 10.1016/j.virol.2017.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2017.07.024</ArticleId><ArticleId IdType="pmc">PMC5571833</ArticleId><ArticleId IdType="pubmed">28750327</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou X, et al. Cholesterol of lipid rafts is a key determinant for entry and post-entry control of porcine rotavirus infection. BMC Vet. Res. 2018;14:45. doi: 10.1186/s12917-018-1366-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12917-018-1366-7</ArticleId><ArticleId IdType="pmc">PMC5809846</ArticleId><ArticleId IdType="pubmed">29433482</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuna-Ramos JF, Reyes-Ruiz JM, Del Angel RM. The role of host cholesterol during flavivirus infection. Front. Cell. Infect. Microbiol. 2018;8:388. doi: 10.3389/fcimb.2018.00388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2018.00388</ArticleId><ArticleId IdType="pmc">PMC6224431</ArticleId><ArticleId IdType="pubmed">30450339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat. Commun. 2021;12:1325. doi: 10.1038/s41467-021-21553-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21553-1</ArticleId><ArticleId IdType="pmc">PMC7910606</ArticleId><ArticleId IdType="pubmed">33637713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. 2020;382:e102. doi: 10.1056/NEJMoa2007621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007621</ArticleId><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XJ, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32:176&#x2013;187 e174. doi: 10.1016/j.cmet.2020.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7311917</ArticleId><ArticleId IdType="pubmed">32592657</ArticleId></ArticleIdList></Reference><Reference><Citation>Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160&#x2013;1164. doi: 10.1126/science.1059344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1059344</ArticleId><ArticleId IdType="pubmed">11349148</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, et al. Cholesterol metabolism&#x2014;Impacts on SARS-CoV-2 infection prognosis. medRxiv. 2020 doi: 10.1101/2020.04.16.20068528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.16.20068528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Chen D, Wu L, He G, Ye W. Declined serum high density lipoprotein cholesterol is associated with the severity of Covid-19 infection. Clin. Chim. Acta. 2020;510:105&#x2013;110. doi: 10.1016/j.cca.2020.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.07.015</ArticleId><ArticleId IdType="pmc">PMC7350883</ArticleId><ArticleId IdType="pubmed">32653486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshikawa T, et al. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS&#xa0;One. 2010;5:e8729. doi: 10.1371/journal.pone.0008729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008729</ArticleId><ArticleId IdType="pmc">PMC2806919</ArticleId><ArticleId IdType="pubmed">20090954</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata-Yoshikawa N, et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J. Virol. 2019 doi: 10.1128/JVI.01815-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01815-18</ArticleId><ArticleId IdType="pmc">PMC6401451</ArticleId><ArticleId IdType="pubmed">30626688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TS, Heinlein C, Hackman RC, Nelson PS. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol. Cell. Biol. 2006;26:965&#x2013;975. doi: 10.1128/MCB.26.3.965-975.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.26.3.965-975.2006</ArticleId><ArticleId IdType="pmc">PMC1347042</ArticleId><ArticleId IdType="pubmed">16428450</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017;142:1&#x2013;10. doi: 10.1016/j.biochi.2017.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2017.07.016</ArticleId><ArticleId IdType="pmc">PMC7116903</ArticleId><ArticleId IdType="pubmed">28778717</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi AD, et al. Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distress. Sci. Rep. 2021;11:9658. doi: 10.1038/s41598-021-88944-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88944-8</ArticleId><ArticleId IdType="pmc">PMC8102547</ArticleId><ArticleId IdType="pubmed">33958627</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai J, et al. Coronavirus infection and cholesterol metabolism. Front. Immunol. 2022;13:791267. doi: 10.3389/fimmu.2022.791267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.791267</ArticleId><ArticleId IdType="pmc">PMC9069556</ArticleId><ArticleId IdType="pubmed">35529872</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffner M, Kumar S. Mammalian HECT ubiquitin-protein ligases: Biological and pathophysiological aspects. Biochim. Biophys. Acta. 1843;61&#x2013;74:2014. doi: 10.1016/j.bbamcr.2013.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.03.024</ArticleId><ArticleId IdType="pubmed">23545411</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt O, Teis D. The ESCRT machinery. Curr. Biol. 2012;22:R116&#x2013;R120. doi: 10.1016/j.cub.2012.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2012.01.028</ArticleId><ArticleId IdType="pmc">PMC3314914</ArticleId><ArticleId IdType="pubmed">22361144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietri M, Radulovic M, Stenmark H. The many functions of ESCRTs. Nat. Rev. Mol. Cell. Biol. 2020;21:25&#x2013;42. doi: 10.1038/s41580-019-0177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-019-0177-4</ArticleId><ArticleId IdType="pubmed">31705132</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z, et al. Ubiquitin ligase WWP1 interacts with Ebola virus VP40 to regulate egress. J. Virol. 2017 doi: 10.1128/JVI.00812-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00812-17</ArticleId><ArticleId IdType="pmc">PMC5625505</ArticleId><ArticleId IdType="pubmed">28768865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda J, Nakao M, Kawaoka Y, Shida H. Nedd4 regulates egress of Ebola virus-like particles from host cells. J. Virol. 2003;77:9987&#x2013;9992. doi: 10.1128/jvi.77.18.9987-9992.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.18.9987-9992.2003</ArticleId><ArticleId IdType="pmc">PMC224586</ArticleId><ArticleId IdType="pubmed">12941909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, et al. The E3 ubiquitin ligase RNF5 facilitates SARS-CoV-2 membrane protein-mediated virion release. mBiol. 2022;13:e0316821. doi: 10.1128/mbio.03168-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03168-21</ArticleId><ArticleId IdType="pmc">PMC8805027</ArticleId><ArticleId IdType="pubmed">35100873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablasser A, Chen ZJ. cGAS in action: Expanding roles in immunity and inflammation. Science. 2019 doi: 10.1126/science.aat8657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat8657</ArticleId><ArticleId IdType="pubmed">30846571</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. Decoding the unknowns in long covid. BMJ. 2021;372:n132. doi: 10.1136/bmj.n132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n132</ArticleId><ArticleId IdType="pubmed">33541867</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, et al. Multi-organ impairment in low-risk individuals with long COVID. medRxiv. 2020 doi: 10.1101/2020.10.14.20212555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.14.20212555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochem. J. 2022;479:537&#x2013;559. doi: 10.1042/BCJ20220016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I, et al. Persistent exertional intolerance after COVID-19: Insights from invasive cardiopulmonary exercise testing. Chest. 2022;161:54&#x2013;63. doi: 10.1016/j.chest.2021.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.08.010</ArticleId><ArticleId IdType="pmc">PMC8354807</ArticleId><ArticleId IdType="pubmed">34389297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittwer CT, Gahl WA, Butler JD, Zatz M, Thoene JG. Metabolism of pantethine in cystinosis. J. Clin. Investig. 1985;76:1665&#x2013;1672. doi: 10.1172/JCI112152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI112152</ArticleId><ArticleId IdType="pmc">PMC424158</ArticleId><ArticleId IdType="pubmed">4056044</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Hamdan M, Gharib B, Bajenoff M, Julia V, de Reggi M. Pantethine down-regulates leukocyte recruitment and inflammatory parameters in a mouse model of allergic airway inflammation. Med. Sci. Monit. Basic Res. 2017;23:368&#x2013;372. doi: 10.12659/msmbr.904077.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msmbr.904077</ArticleId><ArticleId IdType="pmc">PMC5717997</ArticleId><ArticleId IdType="pubmed">29176546</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakillah A, et al. Lipid raft integrity and cellular cholesterol homeostasis are critical for SARS-CoV-2 entry into cells. Nutrients. 2022;14:3417. doi: 10.3390/nu14163417.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14163417</ArticleId><ArticleId IdType="pmc">PMC9415163</ArticleId><ArticleId IdType="pubmed">36014919</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>